Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients
Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not...
Gespeichert in:
Veröffentlicht in: | Nefrología 2001-03, Vol.21 (2), p.167-173 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | spa |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 173 |
---|---|
container_issue | 2 |
container_start_page | 167 |
container_title | Nefrología |
container_volume | 21 |
creator | Armada, E Pérez Melón, C Otero, A Gayoso, P Rodríguez, M Esteban Morcillo, J |
description | Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p < 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p < 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p < 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p < 0.05).
After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71019757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71019757</sourcerecordid><originalsourceid>FETCH-LOGICAL-p540-9fae4bb4c4b29a1586169e4654ae0eac3d2abdfbd82567dd3735945462d7f6b3</originalsourceid><addsrcrecordid>eNo1kEtLAzEcxHNQbK1-BcnJ20KSzaM5SqkPKPSgJy9LHv_QSHazbrJCv70LVhiYy_yGYa7QmjBKG6m1WKHbUr4IkYJpdYNWlHLJpSBr9LkPAVzFOeCQU3TYuOhxmccxQQ9DNTXmAS-quZqET7nP7lwqxAFwgh9IBccBn6DPPpp0LrHgcWEWstyh62BSgfuLb9D78_5j99ocji9vu6dDMwpOGh0McGu545ZpQ8VWUqlhGccNEDCu9cxYH6zfMiGV961qheaCS-ZVkLbdoMe_1nHK3zOU2vWxOEjJDJDn0ilKqFZCLcGHS3C2PfhunGJvpnP3_0X7CwQCW8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71019757</pqid></control><display><type>article</type><title>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Armada, E ; Pérez Melón, C ; Otero, A ; Gayoso, P ; Rodríguez, M ; Esteban Morcillo, J</creator><creatorcontrib>Armada, E ; Pérez Melón, C ; Otero, A ; Gayoso, P ; Rodríguez, M ; Esteban Morcillo, J</creatorcontrib><description>Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p < 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p < 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p < 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p < 0.05).
After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin.</description><identifier>ISSN: 0211-6995</identifier><identifier>PMID: 11464650</identifier><language>spa</language><publisher>Spain</publisher><subject>Aged ; Drug Resistance ; Female ; Folic Acid - administration & dosage ; Folic Acid - blood ; Folic Acid - therapeutic use ; Homocysteine - blood ; Humans ; Hyperhomocysteinemia - complications ; Hyperhomocysteinemia - drug therapy ; Hyperhomocysteinemia - epidemiology ; Hyperhomocysteinemia - prevention & control ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Pyridoxine - administration & dosage ; Pyridoxine - therapeutic use ; Renal Dialysis ; Serum Albumin - analysis ; Spain - epidemiology ; Treatment Outcome ; Urea - blood ; Vitamin B 12 - blood</subject><ispartof>Nefrología, 2001-03, Vol.21 (2), p.167-173</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11464650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Armada, E</creatorcontrib><creatorcontrib>Pérez Melón, C</creatorcontrib><creatorcontrib>Otero, A</creatorcontrib><creatorcontrib>Gayoso, P</creatorcontrib><creatorcontrib>Rodríguez, M</creatorcontrib><creatorcontrib>Esteban Morcillo, J</creatorcontrib><title>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</title><title>Nefrología</title><addtitle>Nefrologia</addtitle><description>Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p < 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p < 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p < 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p < 0.05).
After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin.</description><subject>Aged</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Folic Acid - administration & dosage</subject><subject>Folic Acid - blood</subject><subject>Folic Acid - therapeutic use</subject><subject>Homocysteine - blood</subject><subject>Humans</subject><subject>Hyperhomocysteinemia - complications</subject><subject>Hyperhomocysteinemia - drug therapy</subject><subject>Hyperhomocysteinemia - epidemiology</subject><subject>Hyperhomocysteinemia - prevention & control</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Pyridoxine - administration & dosage</subject><subject>Pyridoxine - therapeutic use</subject><subject>Renal Dialysis</subject><subject>Serum Albumin - analysis</subject><subject>Spain - epidemiology</subject><subject>Treatment Outcome</subject><subject>Urea - blood</subject><subject>Vitamin B 12 - blood</subject><issn>0211-6995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLAzEcxHNQbK1-BcnJ20KSzaM5SqkPKPSgJy9LHv_QSHazbrJCv70LVhiYy_yGYa7QmjBKG6m1WKHbUr4IkYJpdYNWlHLJpSBr9LkPAVzFOeCQU3TYuOhxmccxQQ9DNTXmAS-quZqET7nP7lwqxAFwgh9IBccBn6DPPpp0LrHgcWEWstyh62BSgfuLb9D78_5j99ocji9vu6dDMwpOGh0McGu545ZpQ8VWUqlhGccNEDCu9cxYH6zfMiGV961qheaCS-ZVkLbdoMe_1nHK3zOU2vWxOEjJDJDn0ilKqFZCLcGHS3C2PfhunGJvpnP3_0X7CwQCW8g</recordid><startdate>200103</startdate><enddate>200103</enddate><creator>Armada, E</creator><creator>Pérez Melón, C</creator><creator>Otero, A</creator><creator>Gayoso, P</creator><creator>Rodríguez, M</creator><creator>Esteban Morcillo, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200103</creationdate><title>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</title><author>Armada, E ; Pérez Melón, C ; Otero, A ; Gayoso, P ; Rodríguez, M ; Esteban Morcillo, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p540-9fae4bb4c4b29a1586169e4654ae0eac3d2abdfbd82567dd3735945462d7f6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2001</creationdate><topic>Aged</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Folic Acid - administration & dosage</topic><topic>Folic Acid - blood</topic><topic>Folic Acid - therapeutic use</topic><topic>Homocysteine - blood</topic><topic>Humans</topic><topic>Hyperhomocysteinemia - complications</topic><topic>Hyperhomocysteinemia - drug therapy</topic><topic>Hyperhomocysteinemia - epidemiology</topic><topic>Hyperhomocysteinemia - prevention & control</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Pyridoxine - administration & dosage</topic><topic>Pyridoxine - therapeutic use</topic><topic>Renal Dialysis</topic><topic>Serum Albumin - analysis</topic><topic>Spain - epidemiology</topic><topic>Treatment Outcome</topic><topic>Urea - blood</topic><topic>Vitamin B 12 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Armada, E</creatorcontrib><creatorcontrib>Pérez Melón, C</creatorcontrib><creatorcontrib>Otero, A</creatorcontrib><creatorcontrib>Gayoso, P</creatorcontrib><creatorcontrib>Rodríguez, M</creatorcontrib><creatorcontrib>Esteban Morcillo, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Nefrología</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Armada, E</au><au>Pérez Melón, C</au><au>Otero, A</au><au>Gayoso, P</au><au>Rodríguez, M</au><au>Esteban Morcillo, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients</atitle><jtitle>Nefrología</jtitle><addtitle>Nefrologia</addtitle><date>2001-03</date><risdate>2001</risdate><volume>21</volume><issue>2</issue><spage>167</spage><epage>173</epage><pages>167-173</pages><issn>0211-6995</issn><abstract>Hyperhomocysteinemia is an independent risk factor for cardiovascular mortality in ESRD, but about 80% of total homocysteine (tHcy) is bound to albumin (alb). We have tried, prospectively, to reduce tHcy levels by using folic acid (f.a.) and vitamin B6 (P.P.) supplementation. All patients on HD, not receiving f.a. or P.P. and all new patients, after their third month on HD, were supplemented with f.a. 5 mg/48 hours p.o and P.P. 40 mg/week. We determined folate, P.P. (RIA), vit. B12, KTV, residual renal function (KRU), PCRn, alb and tHcy levels (HPLC). 80 patients, age 62.6 +/- 13.6 years, time on HD 16.2 +/- 25.1 months, all dialysed with AN69 or PPMA, and bicarbonate, were included. The prevalence of hyperhomocysteinemia was 84.4%, and P.P. deficit was present in 32%, with folate in the low normal range. At the beginning of the study, before supplementation, tHcy was negatively correlating only with folate (r = -0.336) (p = 0.01), and not with P.P., vitamin B12, age, albumin, KTV, KRU or PCRn. 58 patients received six months of supplementation, with normalization of P.P. levels, a significant increase of folate (7.25; I.C = 95% confidence intervals: 6.45, 8.05 vs 61.29; I.C.: 44.47, 78.11) (p < 0.001), and decrease of tHcy (24.1; IC: 21.5, 26.3 vs 19.9; I.C: 17.5, 22.4) (p < 0.05). 33 patients have received 12 months of supplementation, but in spite of a continued increase of folate (100.78; I.C: 74.81, 126.74) (p < 0.001), only 3 have normal levels of tHcy; correlating directly tHcy with albumin (r = 0.56) (p = 0.001), that had increased compared to the beginning of the study (3.39; I.C. 3.29, 3.49 vs 3.50; I.C: 3.37, 3.63) (p < 0.05).
After f.a. and P.P. supplementation, though initially tHcy is reduced, this response is short lived, and tHcy directly correlates with albumin levels. Good nutrition associated with HD adequacy, in absence of B vitamin deficits, seems to be the best determinant of tHcy levels rather than its removal by dialysis tHcy levels should be interpreted taking into account the serum albumin.</abstract><cop>Spain</cop><pmid>11464650</pmid><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0211-6995 |
ispartof | Nefrología, 2001-03, Vol.21 (2), p.167-173 |
issn | 0211-6995 |
language | spa |
recordid | cdi_proquest_miscellaneous_71019757 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Aged Drug Resistance Female Folic Acid - administration & dosage Folic Acid - blood Folic Acid - therapeutic use Homocysteine - blood Humans Hyperhomocysteinemia - complications Hyperhomocysteinemia - drug therapy Hyperhomocysteinemia - epidemiology Hyperhomocysteinemia - prevention & control Kidney Failure, Chronic - blood Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Male Middle Aged Prevalence Prospective Studies Pyridoxine - administration & dosage Pyridoxine - therapeutic use Renal Dialysis Serum Albumin - analysis Spain - epidemiology Treatment Outcome Urea - blood Vitamin B 12 - blood |
title | Effect of folic acid supplementation on total homocysteine levels in hemodialysis patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A57%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20folic%20acid%20supplementation%20on%20total%20homocysteine%20levels%20in%20hemodialysis%20patients&rft.jtitle=Nefrolog%C3%ADa&rft.au=Armada,%20E&rft.date=2001-03&rft.volume=21&rft.issue=2&rft.spage=167&rft.epage=173&rft.pages=167-173&rft.issn=0211-6995&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71019757%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71019757&rft_id=info:pmid/11464650&rfr_iscdi=true |